ArticleBriefings in bioinformatics2026
Enhancing TFEA.ChIP with ENCODE regulatory maps for generalizable transcription factor enrichment.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liquiritin restores metabolic homeostasis in NAFLD by modulating AKT1/FOXO1 signaling.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Identifying transcription factors (TFs) responsible for gene expression changes remain a central challenge in functional genomics. TFEA.ChIP is a ChIP-seq-based TF enrichment analysis tool that addresses this by linking TF binding profiles to differentially expressed genes through experimentally supported cis-regulatory element (CRE)-gene associations. Unlike motif- or heuristic-based approaches, TFEA.ChIP adopts a biologically grounded strategy by intersecting TF binding data from ReMap2022 with regulatory maps from ENCODE's rE2G and CREdb. To overcome the high context-specificity of rE2G associations, we developed filtering strategies based on confidence scores and recurrence across biosamples. Benchmarking on 342 curated gene sets from the Molecular Signatures Database C2 CGP collection showed that recurrence-based filtering significantly improved accuracy, outperforming the original GeneHancer-based implementation and leading tools including BARTv2.0, Lisa, ChEA3, and HOMER. A case study on hypoxia further validated the method, demonstrating accurate and pathway-specific enrichment of hypoxia-inducible factor-related TFs using both overrepresentation analysis and gene set enrichment analysis. Additionally, the updated implementation of TFEA.ChIP in R/Bioconductor introduces several user-friendly features, including automated analysis workflows and expression-based filtering of candidate TFs. These additions streamline the integration of TFEA.ChIP into standard RNA-seq analysis pipelines, enabling more efficient and reproducible workflows. Together with its strong benchmarking performance and biologically grounded framework, the updated tool provides a robust and accessible solution for inferring transcriptional regulators from gene expression data.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.